327 related articles for article (PubMed ID: 23765731)
1. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer.
Zenzmaier C; Sampson N; Plas E; Berger P
Prostate; 2013 Sep; 73(13):1441-52. PubMed ID: 23765731
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue.
Zenzmaier C; Untergasser G; Hermann M; Dirnhofer S; Sampson N; Berger P
Prostate; 2008 Apr; 68(5):540-7. PubMed ID: 18247400
[TBL] [Abstract][Full Text] [Related]
3. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation.
Sampson N; Zenzmaier C; Heitz M; Hermann M; Plas E; Schäfer G; Klocker H; Berger P
Endocrinology; 2013 Aug; 154(8):2586-99. PubMed ID: 23720424
[TBL] [Abstract][Full Text] [Related]
4. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells.
Li W; Wu CL; Febbo PG; Olumi AF
Am J Pathol; 2007 Oct; 171(4):1189-98. PubMed ID: 17702894
[TBL] [Abstract][Full Text] [Related]
5. TRAF6 regulates proliferation of stromal cells in the transition and peripheral zones of benign prostatic hyperplasia via Akt/mTOR signaling.
Shi YF; Yu DJ; Jiang CY; Wang XJ; Zhu YP; Zhao RZ; Lv Z; Sun XW
Prostate; 2018 Feb; 78(3):193-201. PubMed ID: 29171041
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone inhibits arylsulfatase B and Dickkopf Wnt signaling pathway inhibitor (DKK)-3 leading to enhanced Wnt signaling in prostate epithelium in response to stromal Wnt3A.
Bhattacharyya S; Feferman L; Tobacman JK
Prostate; 2019 May; 79(7):689-700. PubMed ID: 30801800
[TBL] [Abstract][Full Text] [Related]
7. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation.
Untergasser G; Gander R; Lilg C; Lepperdinger G; Plas E; Berger P
Mech Ageing Dev; 2005 Jan; 126(1):59-69. PubMed ID: 15610763
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.
Hamakawa T; Sasaki S; Shibata Y; Imura M; Kubota Y; Kojima Y; Kohri K
Prostate; 2014 May; 74(6):590-601. PubMed ID: 24615654
[TBL] [Abstract][Full Text] [Related]
9. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
Zenzmaier C; Sampson N; Pernkopf D; Plas E; Untergasser G; Berger P
Endocrinology; 2010 Aug; 151(8):3975-84. PubMed ID: 20555034
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
Zenzmaier C; Kern J; Sampson N; Heitz M; Plas E; Untergasser G; Berger P
Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
[TBL] [Abstract][Full Text] [Related]
11. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.
Al Shareef Z; Kardooni H; Murillo-Garzón V; Domenici G; Stylianakis E; Steel JH; Rabano M; Gorroño-Etxebarria I; Zabalza I; Vivanco MD; Waxman J; Kypta RM
Oncogene; 2018 Sep; 37(39):5305-5324. PubMed ID: 29858602
[TBL] [Abstract][Full Text] [Related]
13. Abnormal expression of Rab27B in prostatic epithelial cells of benign prostatic hyperplasia alters intercellular communication.
Dai Y; Ai B; Liu Y; Pascal LE; Wang Z; Dhir R; Sun X; Jiang Y
Int J Biochem Cell Biol; 2021 Feb; 131():105898. PubMed ID: 33285290
[TBL] [Abstract][Full Text] [Related]
14. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
15. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia.
Wang W; Zhang X; Mize GJ; Takayama TK
Prostate; 2008 Jul; 68(10):1064-75. PubMed ID: 18386288
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.
Antony L; van der Schoor F; Dalrymple SL; Isaacs JT
Prostate; 2014 Aug; 74(11):1118-31. PubMed ID: 24913829
[TBL] [Abstract][Full Text] [Related]
19. M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin-like growth factor 1 knockdown.
Qian Q; He W; Liu D; Yin J; Ye L; Chen P; Xu D; Liu J; Li Y; Zeng G; Li M; Wu Z; Zhang Y; Wang X; DiSanto ME; Zhang X
Prostate; 2021 Jun; 81(9):530-542. PubMed ID: 33861464
[TBL] [Abstract][Full Text] [Related]
20. VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia.
Mori F; Tanigawa K; Endo K; Minamiguchi K; Abe M; Yamada S; Miyoshi K
Prostate; 2011 Oct; 71(14):1579-86. PubMed ID: 21394740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
